Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) Short Interest Up 279.6% in May

Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) was the target of a large increase in short interest in May. As of May 15th, there was short interest totaling 441,245 shares, an increase of 279.6% from the April 30th total of 116,241 shares. Based on an average daily volume of 3,204,496 shares, the days-to-cover ratio is presently 0.1 days. Currently, 8.6% of the company’s stock are short sold.

Institutional Trading of Shuttle Pharmaceuticals

Hedge funds and other institutional investors have recently modified their holdings of the stock. Geode Capital Management LLC acquired a new position in Shuttle Pharmaceuticals during the fourth quarter valued at approximately $26,000. Boothbay Fund Management LLC acquired a new position in shares of Shuttle Pharmaceuticals during the 4th quarter worth approximately $37,000. Ikarian Capital LLC bought a new stake in shares of Shuttle Pharmaceuticals during the 4th quarter worth approximately $124,000. Finally, Connective Capital Management LLC bought a new stake in shares of Shuttle Pharmaceuticals during the 3rd quarter worth approximately $357,000. Institutional investors and hedge funds own 4.58% of the company’s stock.

Shuttle Pharmaceuticals Stock Down 2.4%

Shares of SHPH opened at $0.53 on Friday. Shuttle Pharmaceuticals has a twelve month low of $0.50 and a twelve month high of $6.19. The stock has a market capitalization of $3.07 million, a P/E ratio of -0.11 and a beta of 0.38. The company has a 50 day moving average of $0.78 and a 200-day moving average of $1.30.

Shuttle Pharmaceuticals (NASDAQ:SHPH) last released its earnings results on Friday, May 15th. The company reported ($0.43) earnings per share for the quarter.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings cut shares of Shuttle Pharmaceuticals from a “sell (e+)” rating to a “sell (e)” rating in a report on Monday, May 18th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat, Shuttle Pharmaceuticals currently has a consensus rating of “Sell”.

Shuttle Pharmaceuticals Company Profile

Shuttle Pharmaceuticals Holdings, Inc, a clinical stage pharmaceutical company, develops novel therapies to cure cancers. It develops Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and sarcomas SP-1-161, an HDAC inhibitor that initiates the mutated in ataxia-telangiectasia response pathway for radiation sensitizing cancer cells and protecting normal cells; SP-2-225, a pre-clinical class IIb that effects on the regulation of the immune system; and SP-1-303, a pre-clinical selective Class I HDAC for the treatment of ER positive cancers .